Loading
IntoCell is a Korean company that develops the chemical linkers and drug payloads used to build antibody-drug conjugates, antibodies that carry a cell-killing drug to cancer cells. Its first own candidate, ITC-6146RO, entered a phase 1 trial in 2026.
IntoCell, Inc., based in Daejeon, Korea, was founded in April 2015, according to the company history, and listed on the KOSDAQ market in May 2025. Its core technologies are the OHPAS linker, Nexatecan payload and other drug-conjugate technologies, and its history records a B7-H3 ADC research collaboration from 2017, a 2022 material transfer agreement with an option with ADC Therapeutics, a 2023 joint research agreement with Samsung Bioepis and a 2024 licence agreement with ABL Bio. ITC-6146RO received FDA clearance of its phase 1 investigational new drug application in November 2025 and Korean MFDS approval in December 2025. Its first registered cancer trial, NCT07423117, a phase 1a/b first-in-human dose-escalation and expansion study of ITC-6146RO in advanced or metastatic cancers including metastatic castration-resistant prostate cancer, non-small cell lung cancer and triple-negative breast cancer, was posted on ClinicalTrials.gov in February 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/